Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 157 to 158 of 158 entries
Sorted by: Best Match Show Resources per page
Performance of a HER2 testing algorithm specific for p53-abnormal endometrial cancer.

Histopathology

Vermij L, Singh N, Leon-Castillo A, Horeweg N, Oosting J, Carlson J, Smit V, Gilks B, Bosse T.
PMID: 33835523
Histopathology. 2021 Oct;79(4):533-543. doi: 10.1111/his.14381. Epub 2021 Jul 05.

AIMS: Human epidermal growth factor receptor 2 (HER2) amplification in endometrial cancer (EC) is almost completely confined to the p53-abnormal (p53abn) molecular subtype and independent of histological subtype. HER2 testing should therefore be molecular subtype-directed. However, the most optimal...

Cite
Vermij L, Singh N, Leon-Castillo A, et al. Performance of a HER2 testing algorithm specific for p53-abnormal endometrial cancer. Histopathology. 2021;79(4):533-543doi: 10.1111/his.14381.
Vermij, L., Singh, N., Leon-Castillo, A., Horeweg, N., Oosting, J., Carlson, J., Smit, V., Gilks, B., & Bosse, T. (2021). Performance of a HER2 testing algorithm specific for p53-abnormal endometrial cancer. Histopathology, 79(4), 533-543. https://doi.org/10.1111/his.14381
Vermij, Lisa, et al. "Performance of a HER2 testing algorithm specific for p53-abnormal endometrial cancer." Histopathology vol. 79,4 (2021): 533-543. doi: https://doi.org/10.1111/his.14381
Vermij L, Singh N, Leon-Castillo A, Horeweg N, Oosting J, Carlson J, Smit V, Gilks B, Bosse T. Performance of a HER2 testing algorithm specific for p53-abnormal endometrial cancer. Histopathology. 2021 Oct;79(4):533-543. doi: 10.1111/his.14381. Epub 2021 Jul 05. PMID: 33835523; PMCID: PMC8518500.
Copy Download .nbib Format: NLM
SATB2 Expression in Uterine Sarcoma: A Multicenter Retrospective Study.

International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists

Le Page C, Almadani N, Turashvili G, Bataillon G, Portelance L, Provencher D, Mes-Masson AM, Gilks B, Hoang L, Rahimi K.
PMID: 33720083
Int J Gynecol Pathol. 2021 Sep 01;40(5):487-494. doi: 10.1097/PGP.0000000000000730.

Uterine sarcomas represent a clinical challenge because of their difficult diagnosis and the poor prognosis of certain subtypes. The aim of this study was to evaluate the expression of the special AT-rich sequence-binding protein 2 (SATB2) in endometrial stromal...

Cite
Le Page C, Almadani N, Turashvili G, et al. SATB2 Expression in Uterine Sarcoma: A Multicenter Retrospective Study. Int J Gynecol Pathol. 2021;40(5):487-494doi: 10.1097/PGP.0000000000000730.
Le Page, C., Almadani, N., Turashvili, G., Bataillon, G., Portelance, L., Provencher, D., Mes-Masson, A. M., Gilks, B., Hoang, L., & Rahimi, K. (2021). SATB2 Expression in Uterine Sarcoma: A Multicenter Retrospective Study. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists, 40(5), 487-494. https://doi.org/10.1097/PGP.0000000000000730
Le Page, Cécile, et al. "SATB2 Expression in Uterine Sarcoma: A Multicenter Retrospective Study." International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists vol. 40,5 (2021): 487-494. doi: https://doi.org/10.1097/PGP.0000000000000730
Le Page C, Almadani N, Turashvili G, Bataillon G, Portelance L, Provencher D, Mes-Masson AM, Gilks B, Hoang L, Rahimi K. SATB2 Expression in Uterine Sarcoma: A Multicenter Retrospective Study. Int J Gynecol Pathol. 2021 Sep 01;40(5):487-494. doi: 10.1097/PGP.0000000000000730. PMID: 33720083.
Copy Download .nbib Format: NLM
Showing 157 to 158 of 158 entries